NPPB

There are 148 papers on NPPB in aging research: 21 trials and 92 observational studies in people, 26 in animals, 2 in cells, 6 reviews. The newest story, Oct 4, 2026: “Blood proteins improve early cardiometabolic risk prediction”.

Gene

148 papers study it13 findings

HGNCNCBI GeneTaxon

7 new papers in 30 daysSee all 148 papers on NPPB

At a glance

The findings reach people, from one lab or study. 6 independent labs in 3 countries.

“Weight-adjusted protein-specific estimates were significant for THBS2 (11.1%), NPPB (32.6%), ANGPT2 (19.3%), and CD93 (35.8%).”
Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT TrialADA Scientific Sessions 2026 abstract2026doi:10.2337/db26-1291-or

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 6 independent labs in 3 countries
  • Funders: National Heart, Lung, and Blood Institute and 8 more
  • 1 of 11 findings with company ties
  • Human trial21
  • Humans92
  • Animals26
  • Cells2
  • In silico1

Interventions

2

Pulmonary rehabilitation

downin humans1

1 study
  1. Pulmonary rehabilitation decreases NPPB in humans (patients with idiopathic pulmonary fibrosis on background antifibrotic therapy).

    Human trialpatients with idiopathic pulmonary fibrosis on background antifibrotic therapyremotely monitored home PRplasma12 weeksn = 15

More on Pulmonary rehabilitation

Caloric restriction

downin mice1

1 study
  1. Caloric restriction decreases NPPB in mice.

    Animalslong-term caloric restrictionheartmales

More on Caloric restriction

Effects

3

Major adverse cardiovascular events

mediatesin humans1

1 study
  1. NPPB mediates major adverse cardiovascular events in humans (weight-adjusted mediation analysis) (32.6% mediated).

    Human trialweight-adjusted mediation analysis3 years

More on Major adverse cardiovascular events

Coronary artery disease

downin silico1

1 study
  1. NPPB inhibits coronary artery disease in path model using plasma BNP drawn by VHD (β: -0.465, P < 0.001).

    In silicoin path model using plasma BNP drawn by VHDn = 3,457

More on Coronary artery disease

Lifespan

upin humans1

1 study
  1. NPPB is linked with longer lifespan in humans (GG genotype vs AA genotype) (+8 months).

    HumansGG genotype vs AA genotypemedian follow-up of 23 yearsn = 11,361

Associations

8

FAP

upin silico1

1 study
  1. FAP is associated with NPPB in silico mapping and proteolytic assays.

    In silicoin silico mapping and proteolytic assays

More on FAP

Heart failure

upin humans1

1 study
  1. NPPB predicts heart failure in humans after adjusting for matching variables and clinical risk factors.

    Humansafter adjusting for matching variables and clinical risk factors

More on Heart failure

Cardioembolic ischemic stroke

upin humans1

1 study
  1. NPPB is linked with a higher risk of cardioembolic ischemic stroke in humans (free of prevalent stroke).

    Humansfree of prevalent strokemedian follow-up of 12.6 yearsn = 2,983

More on Cardioembolic ischemic stroke

Ischemic stroke

upin humans1HR 1.37

1 study
  1. NPPB is linked with a higher risk of ischemic stroke in humans (free of prevalent stroke) (adjusted HR 1.37, 95% CI 1.23-1.53, p = 2.08 × 10−08).

    Humansfree of prevalent strokemedian follow-up of 12.6 yearsn = 2,983

More on Ischemic stroke

Atrial fibrillation

upin humans1HR 1.82

1 study
  1. NPPB is linked with a higher risk of atrial fibrillation in humans after adjustment for clinical factors associated with AF (HR 1.82, 95% CI 1.68 to 1.98).

    Humansafter adjustment for clinical factors associated with AFplasma5.7 ± 1.7 yearsn = 4,668

More on Atrial fibrillation

Mortality

downin humans1HR 0.86

1 study
  1. NPPB is associated with mortality in humans (GG genotype vs AA genotype) (HR 0.86, 95% CI 0.78-0.95).

    HumansGG genotype vs AA genotypemedian follow-up of 23 yearsn = 11,361

Hypertension

downin humans1OR 0.81

1 study
  1. NPPB is linked with a lower risk of hypertension in humans (GG genotype vs AA genotype) (OR 0.81, 95% CI 0.72-0.92).

    HumansGG genotype vs AA genotypen = 11,361

More on Hypertension

NT-proBNP

upin humans1+41% higher

1 study
  1. NPPB is associated with NT-proBNP in humans (GG genotype vs AA genotype) (41% higher).

    HumansGG genotype vs AA genotypen = 11,361

More on NT-proBNP

Latest

Dec 2025: 4Jan 2026: 5Feb 2026: 4Mar 2026: 4Apr 2026: 2May 2026: 2Jun 2026: 4Jul 2026: 4Aug 2026: 2Sep 2026: 5Oct 2026: 5Nov 2026: 243 papers in 12 months
Diabetes, Obesity & Metabolism

Blood proteins improve early cardiometabolic risk prediction

In 43,709 adults with early-stage disease, outcome-specific proteomic signatures improved clinical risk discrimination across 11 incident outcomes, boosting C-index…In 43,709 adults with early-stage disease, outcome-specific proteomic signatures improved clinical risk discrimination across 11 incident outcomes, boosting C-index values by 0.024 to 0.070.

Cohort study of 43,709 peopleBiomarkers

See all 148 papers on NPPB